Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial

Journal of Psychopharmacology

Volumn 28, Issue 7, 2014, Pages 677-685

  Ghaleiha, Ali ^a   Ghyasvand, Mohammad ^b   Mohammadi, Mohammad Reza ^b   Farokhnia, Mehdi ^b   Yadegari, Noorollah ^b   Tabrizi, Mina ^c   Hajiaghaee, Reza ^d   Yekehtaz, Habibeh ^b   Akhondzadeh, Shahin ^b  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Institute of Medicinal Plants   (Iran)

Author keywords

Acetylcholinesterase inhibitor; autism; cholinergic; galantamine; irritability; nicotinic receptor; randomized controlled trial; risperidone; social withdrawal

Indexed keywords

GALANTAMINE; REMINY; RISPERIDONE; UNCLASSIFIED DRUG; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT;

ABERRANT BEHAVIOR CHECKLIST COMMUNITY IRRITABILITY SUBSCALE; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERACTIVITY SUBSCALE; INAPPROPRIATE SPEECH SUBSCALE; INCREASED APPETITE; LETHARGY SUBSCALE; MALE; NERVOUSNESS; NONCOMPLIANCE SUBSCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SOCIAL WITHDRAWAL SUBSCALE; STEREOTYPIC BEHAVIOR SUBSCALE; TREATMENT DURATION; WEIGHT GAIN; CHECKLIST; CHILD BEHAVIOR; COMBINATION DRUG THERAPY; DRUG EFFECTS; IRAN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PSYCHOLOGY; QUESTIONNAIRE; TIME FACTOR; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHECKLIST; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GALANTAMINE; HUMANS; IRAN; MALE; RISPERIDONE; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902585877     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113508830     Document Type: Article

References (54)

1. Abreu-Villaca Y, Filgueiras CC, Manhaes AC. Developmental aspects of the cholinergic system. Behav Brain Res. 2011 ; 221: 367-378
2. Ago Y, Koda K, Takuma K, et al. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci. 2011 ; 116: 6-17
3. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010 ; 34: 32-36
4. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985 ; 89: 485-491
5. Diagnostic Criteria from Dsm-Iv-Tr. Washington, DC: American Psychiatric Association ; 2000 :
6. Asadabadi M, Mohammadi MR, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. Psychopharmacology. 2013 ; 225: 51-59
7. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: A review and future directions. Int J Dev Neurosci. 2005 ; 23: 183-187
8. Belluardo N, Mudo G, Blum M, et al. Neurotrophic effects of central nicotinic receptor activation. J Neural Transm. 2000 ; 60: 227-245
9. Bentley P, Vuilleumier P, Thiel CM, et al. Cholinergic enhancement modulates neural correlates of selective attention and emotional processing. Neuroimage. 2003 ; 20: 58-70
10. Blaylock RL, Strunecka A. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. Curr Med Chem. 2009 ; 16: 157-170
11. Bruel-Jungerman E, Lucassen PJ, Francis F. Cholinergic influences on cortical development and adult neurogenesis. Behav Brain Res. 2011 ; 221: 379-388
12. Chilian B, Abdollahpour H, Bierhals T, et al. Dysfunction of Shank2 and Chrna7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci. Clin Genet. 2013 ; 8: e1002521
13. Clementi F, Fornasari D, Gotti C. Neuronal nicotinic receptors, important new players in brain function. Eur J Pharmacol. 2000 ; 393: 3-10
14. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev. 2006 ;: CD004746
15. Dajas-Bailador FA, Heimala K, Wonnacott S. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol. 2003 ; 64: 1217-1226
16. De Souza FM, Busquet N, Blatner M, et al. Galantamine improves olfactory learning in the Ts65dn mouse model of Down syndrome. Sci Rep. 2011 ; 1: e00137
17. Deutsch SI, Urbano MR, Neumann SA, et al. Cholinergic abnormalities in autism: Is there a rationale for selective nicotinic agonist interventions?. Clin Neuropharmacol. 2010 ; 33: 114-120
18. Friedman SD, Shaw DW, Artru AA, et al. Regional brain chemical alterations in young children with autism spectrum disorder. Neurology. 2003 ; 60: 100-107
19. Ghaemi SN, Gilmer WS, Dunn RT, et al. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol. 2009 ; 29: 291-295
20. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2013 ; 16: 783-789
21. Hasanzadeh E, Mohammadi MR, Ghanizadeh A, et al. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum Dev. 2012 ; 43: 674-682
22. Hertzman M. Galantamine in the treatment of adult autism: A report of three clinical cases. Int J Psychiatry Med. 2003 ; 33: 395-398
23. Kumar B, Prakash A, Sewal RK, et al. Drug therapy in autism: A present and future perspective. Pharmacol Rep. 2012 ; 64: 1291-1304
24. Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: A review of the iterature. Res Dev Disabil. 2006 ; 27: 254-289
25. Lee M, Martin-Ruiz C, Graham A, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain. 2002 ; 125: 1483-1495
26. Litvinenko IV, Odinak MM, Mogil'naya VI, et al. Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol. 2008 ; 38: 937-945
27. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview - Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994 ; 24: 659-685
28. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 ;: CD001747
29. Madaan V, Kinnan S, Daughton J, et al. Innovations and recent trends in the treatment of ADHD. Expert Rev Neurother. 2006 ; 6: 1375-1385
30. Maelicke A, Samochocki M, Jostock R. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry. 2001 ; 49: 279-288
31. Martin-Ruiz CM, Lee M, Perry RH, et al. Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res. 2004 ; 123: 81-90
32. Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/ neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm. 2007 ; 114: 135-147
33. Nelson KB, Grether JK, Croen LA, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001 ; 49: 597-606
34. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006a ; 16: 621-629
35. Nicolson R, Devito TJ, Vidal CN, et al. Detection and mapping of hippocampal abnormalities in autism. Psychiatry Res. 2006b ; 148: 11-21
36. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. Brit Med J. 2002 ; 325: 1422
37. Noda Y, Mouri A, Ando Y, et al. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: Involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-Erk1/2 systems. Int J Neuropsychopharmacol. 2010 ; 13: 1343-1354
38. Ochoa EL, Clark E. Galantamine improve attention and speech in schizophrenia. Hum Psychopharmacol. 2006 ; 21: 127-128
39. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. 2001 ; 158: 1058-1066
40. Petersen AK, Ahmad A, Shafiq M, et al. Deletion 1q43 encompassing only Chrm3 in a patient with autistic disorder. Eur J Med Genet. 2013 ; 56: 118-122
41. Ray MA, Graham AJ, Lee M, et al. Neuronal nicotinic acetylcholine receptor subunits in autism: An immunohistochemical investigation in the thalamus. Neurobiol Dis. 2005 ; 19: 366-377
42. Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010 ; 34: 1269-1272
43. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: A systematic review. Ann Clin Psychiatry. 2009 ; 21: 213-236
44. Rubenstein JL, Merzenich MM. Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003 ; 2: 255-267
45. Santos MD, Alkondon M, Pereira EF, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol. 2002 ; 61: 1222-1234
46. Schilstrom B, Ivanov VB, Wiker C, et al. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacol. 2007 ; 32: 43-53
47. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry. 2006 ; 60: 530-533
48. Sharp BM, Yatsula M, Fu Y. Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther. 2004 ; 309: 1116-1123
49. Sokol DK, Dunn DW, Edwards-Brown M, et al. Hydrogen proton magnetic resonance spectroscopy in autism: Preliminary evidence of elevated choline/creatine ratio. J Child Neurol. 2002 ; 17: 245-249
50. Wang D, Noda Y, Zhou Y, et al. Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacol. 2007 ; 52: 1179-1187
51. Wiker C, Schilstrom B, Sandback C, et al. Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats. Int J Neuropsychopharmacol. 2008 ; 11: 845-850
52. Wilens TE, Biederman J, Wong J, et al. Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. J Child Adolesc Psychopharmacol. 2000 ; 10: 217-222
53. Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol. 1991 ; 37: 475-524
54. Yasui DH, Scoles HA, Horike S, et al. 15q11.2-13.3 Chromatin analysis reveals epigenetic regulation of Chrna7 with deficiencies in Rett and autism brain. Hum Mol Genet. 2011 ; 20: 4311-4323